Skip to main content

Day: June 3, 2022

Noranda Income Fund Reaches Agreement on Terms for 2022/2023 Contractual Period

TORONTO, June 03, 2022 (GLOBE NEWSWIRE) — Noranda Income Fund (TSX:NIF.UN) (the “Fund”) announced today that it has reached an agreement with Glencore Canada on the terms under which zinc concentrate will be purchased and zinc metal will be sold for the period of May 1, 2022, to April 30, 2023 (the “2022/2023 contractual period”). For the 2022/2023 contractual period, the Fund’s purchases of primary zinc concentrates will be made 60% at a fixed treatment charge and 40% at a variable treatment charge that will fluctuate in line with market movements, among other conditions. The Fund and Glencore Canada agreed upon a fixed premium price on zinc metal sales for the same May 1 to April 30 contractual period. Detailed terms are not disclosed as they are considered commercially sensitive and confidential. As per the agreements in place,...

Continue reading

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations, including one oral and two poster presentations, highlighting data from exploratory and pooled analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to the presentations are included below. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are pleased to have presented three data sets at the CMSC conference yesterday. We believe these data further support the previously reported positive Phase 3 results from the ULTIMATE I and II studies.” Mr. Weiss continued, “We continue to be encouraged by the feedback received...

Continue reading

Aehr Test Systems to Present at LD Micro Invitational Conference on June 8, 2022

FREMONT, Calif., June 03, 2022 (GLOBE NEWSWIRE) — Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced that CEO and President Gayn Erickson will be presenting at the LD Micro 12th Annual Invitational Conference on Wednesday, June 8th at 12:00pm PT at the Four Seasons Hotel in Westlake Village, CA, and will be meeting with investors throughout the day. You may register to watch the presentation here. “We look forward to discussing our semiconductor wafer level and singulated die test and burn-in solutions and the markets they serve with investors,” said Mr. Erickson. “Aehr Test provides complete production solutions for improving yield and reliability of semiconductors, and devices such as silicon carbide semiconductors used in electric and hybrid electric...

Continue reading

Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference

BOSTON, June 03, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET. A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology company dedicated...

Continue reading

Knight to Present at the Jefferies 2022 Healthcare Conference in New York City

MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City. A copy of the presentation will be available at www.gud-knight.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under...

Continue reading

Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC

COBALT study in advanced PBC, previously terminated early due to feasibility challenges, did not demonstrate a statistically significant difference in clinical endpoints between Ocaliva® and placebo HEROES-US real-world analysis demonstrated statistically significant improvement in event-free survival in patients receiving Ocaliva for PBC Intercept plans to include these data in an evidence package that will be submitted to U.S. FDA in 2H 2022 to support post-marketing regulatory requirements MORRISTOWN, N.J., June 03, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced results from two studies designed to evaluate clinical outcomes in patients with PBC on Ocaliva...

Continue reading

Blockmate Investor Update Replay

LONDON and AMSTERDAM, June 03, 2022 (GLOBE NEWSWIRE) — Blockmate Ventures Inc. (TSX.V: MATE) (FSE: 8MH1) (“Blockmate” or the “Company”) has uploaded a recording of the online investor briefing held on June 2nd, 2022 to its website, featuring an update from Blockmate CEO & President Dom Carosa. The recording can be viewed here: https://www.blockmate.com/videos The Investor deck can be download here: https://bit.ly/Blockmate-Deck-2June2022 The briefing included updates for investors on:Blockmate’s blockchain incubation vision and successful track record of projects The Hivello revenue model and regional targets for IoT hotspots An updated strategy for Blockmate’s asset Midpoint with ways to maximise revenue A new consumer-focused de-fi (decentralized finance) platform – Yield OTCBlockmate welcomes investors...

Continue reading

SpotLite360 IOT Solutions, Inc. Releases Q1 2022 Financial Results

DENVER and VANCOUVER, British Columbia, June 03, 2022 (GLOBE NEWSWIRE) — SPOTLITE360 IOT SOLUTIONS, INC. (“SpotLite360” or the “Company”) (CSE: LITE) (OTC: SPLTF) (Frankfurt: 87A) is pleased to announce that it has released financial and operational results for the first quarter of 2022 (“Q1 22”). Readers are encouraged to review the March 31, 2022 Consolidated Financial Statements and Management’s Discussion & Analysis (MD&A) which were filed on SEDAR (www.sedar.com) on May 30, 2022. All results are expressed in Canadian dollars unless otherwise specified. SpotLite360 posted a significant increase of $0.745 million in Q1 22, up from $0.199 million in Q4 21, for total revenue of $0.944 million in Q1 22 with continued investment in operations, sales, product development and delivery of enterprise scalable solutions. The...

Continue reading

Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time. Investors and the general public are invited to listen to the Goldman Sachs fireside chat, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com. ABOUT MYOVANT SCIENCESMyovant Sciences aspires to redefine care for women and for...

Continue reading

Vasta announces investment in Educbank

SÃO PAULO, Brazil, June 03, 2022 (GLOBE NEWSWIRE) — Vasta Platform Limited (NASDAQ: VSTA) announces the execution of a minority investment agreement by its wholly-owned subsidiary, Somos Sistemas de Ensino S.A. (“Somos”), which establishes the terms and conditions for the issuance and the payment of new shares on Educbank Gestão de Pagamentos Educacionais S.A. (“Educbank”). According to the agreement, the investment will be made in installments over a two-year period, upon subscription of new Educbank shares, according to the growth of students served by Educbank and other conditions. The closing of the transaction is subject to certain conditions precedent, including the approval by the Brazilian antitrust authority. Educbank is the first financial ecosystem dedicated to K-12 schools, intended to expand access to quality education...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.